Skip to content
Menu

Oruka Therapeutics, Inc. ORKA

Full chart Compare
Set alert

Price alert · ORKA

All alert types
97.57 USD +1.83 (+1.91%)

Regular-session close

97.57 0.00 0.00%

After hours · Nov 19, 4:00 PM ET

96.11 Day range 101.94
25.23 52-week range 115.52
YTD
+221.91%
1 year
+245.26%

5D -5.75 (-5.56%)

95100105FriMonTueWedThu97.70
Market cap
6.62B
EPS (ttm)
-2.12
Shares out
67.82M
Forward P/E
-34.09
YTD return
+221.91%
1-year return
+245.26%
50-day average
89.94
200-day average
73.59
Enterprise value
5.58B
Price / book
5.49
Volume
927.12K
Avg volume
949.00K
Open
96.70
Previous close
95.74
Day's range
96.11 – 101.94
52-week range
25.23 – 115.52
Beta
-0.17
Analysts
Strong Buy
Price target
156.17 (+60.1%)
Earnings date
Mar 11, 2027

Key statistics

Free cash flow
-91.81M
Total cash
920.28M
Total debt
2.93M
Return on equity
-18.12%
Short % of float
13.90%

Fundamental scorecard

3 of 25 checks passed on ORKA’s reported financials

ValueGrowthProfitabilityHealthDividend

3of 25 checks passed

  • Value 0 of 5
  • Growth 0 of 5
  • Profitability 0 of 5
  • Financial health 3 of 5
  • Dividend 0 of 5

Statements to Sep 30, 2026.

Financials — quick view

All financials
ORKA Revenue — quarterly 0
ORKA Net income — quarterly -49.97M
ORKA EPS — quarterly -0.63

Earnings

ORKA recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Mar 11, 2027Dec 30, 2026-0.78———
Nov 9, 2026Sep 30, 2026-0.59959-0.63-0.03-5.07%
Aug 10, 2026Jun 30, 2026-0.51249-0.55-0.04-7.32%
May 13, 2026Mar 31, 2026-0.54692-0.48+0.07+12.24%
Mar 12, 2026Dec 31, 2025-0.61-0.45+0.16+26.23%
Nov 12, 2025Sep 30, 2025-0.56-0.55+0.01+1.79%

Upgrades / downgrades

ORKA analyst upgrades and downgrades
DateFirmActionFromTo
Nov 10, 2026BTIGreitBuyBuy
Oct 27, 2026GuggenheimreitBuyBuy
Oct 27, 2026WedbushreitOutperformOutperform
Oct 19, 2026BTIGreitBuyBuy
Sep 24, 2026WedbushreitOutperformOutperform
Sep 24, 2026HC Wainwright & Co.reitBuyBuy

About Oruka Therapeutics, Inc.

Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO), and other inflammatory and immunology (I&I) indications. Its lead products include ORKA-001 that targets p19 subunit of interleukin-23, which is in phase 2a trial for the treatment of PsO; and ORKA-002 that targets interleukin-17A and interleukin-17F, which is in phase 2 trial for the treatment of PsO, psoriatic arthritis, and other conditions. The company also develops ORKA-003 for targeting an undisclosed pathway; and ORKA-021, a sequential combination regimen of ORKA-002 and ORKA-001. Oruka Therapeutics, Inc. is headquartered in Menlo Park, California.

Sector
Healthcare
Industry
Biotechnology
Country
United States
Website
orukatx.com

News

Your note

Sign in to keep a note on ORKA — it syncs with the Stock Master app.

Insider holders

ORKA insider holders
InsiderRelationLatest transactionDateShares held
AGARWAL ARJUNOfficerSaleOct 11, 202614,219
BALL KRISTINE M.DirectorSaleNov 11, 20260
DAMBKOWSKI CARLDirectorSaleJun 11, 202638,743
EDWARDS LARRY TODDOfficerStock Award(Grant)Aug 23, 2026100,000
FAIRMOUNT FUNDS MANAGEMENT LLCBeneficial Owner of more than 10% of a Class of SecuritySaleJun 30, 20260
GONCALVES JOANAOfficerSaleNov 15, 202631,771

Institution ownership

ORKA institution ownership
Holder% heldSharesValueReported
FMR, LLC14.96%10,148,867990.22MSep 29, 2026
Blackrock Inc.7.68%5,210,214508.36MSep 29, 2026
T. Rowe Price Investment Management, Inc.6.48%4,392,166428.54MSep 29, 2026
Venrock Adviser, LLC6.12%4,148,428404.76MSep 29, 2026
Fairmount Funds Management LLC5.46%3,705,262361.52MSep 29, 2026
Capital World Investors5.06%3,429,066334.57MSep 29, 2026

Fund ownership

ORKA fund ownership
Holder% heldSharesValueReported
VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund2.54%1,724,692168.28MJun 29, 2026
SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF2.38%1,614,957157.57MSep 29, 2026
SmallCap World Fund Inc2.25%1,527,592149.05MSep 29, 2026
New Economy Fund1.95%1,323,308129.12MSep 29, 2026
iShares Trust-iShares Russell 2000 ETF1.92%1,304,825127.31MSep 29, 2026
Fidelity Mt. Vernon Street Trust-Fidelity Growth Company Fund1.91%1,294,135126.27MSep 29, 2026